NCT02215096View on ClinicalTrials.gov

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 13, 2014

Primary Completion Date

October 3, 2019

Study Completion Date

October 3, 2019

Conditions
Neoplasms
Interventions
DRUG

GSK2636771

GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water

DRUG

Enzalutamide

Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved

Trial Locations (9)

10016

GSK Investigational Site, New York

20007

GSK Investigational Site, Washington D.C.

48201

GSK Investigational Site, Detroit

77030

GSK Investigational Site, Houston

90033

GSK Investigational Site, Los Angeles

90095

GSK Investigational Site, Los Angeles

91010

GSK Investigational Site, Duarte

SE1 9RT

GSK Investigational Site, London

SM2 5PT

GSK Investigational Site, Sutton

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02215096 - Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter